Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals (NQ: ALNY )

253.74 +0.39 (+0.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
  
Via Benzinga
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Expert Ratings for Alnylam Pharmaceuticals
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
Via Benzinga
Analyst Ratings for Alnylam Pharmaceuticals
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
Via Benzinga
Alnylam's Lumasiran Shows Clinical Benefit In Rare Kidney Disease
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Daily Biotech Pulse: GSK's Kidney Disease Drug Approved For Children, Tonix Pharma To Launch Monkeypox Vaccine Study In Kenya, Positive Effect Of Cyclerion's Schizophrenia Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Alnylam Pharmaceuticals: Q2 Earnings Insights
  Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q2 earnings results on Thursday, July 28, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Uncovers Genetic Mutations in INHBE That Protect Against Abdominal Obesity
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Amid RNA Setbacks, Start Up Bets On Sanofi's siRNA Platform
Via Benzinga
Alnylam to Webcast Conference Call Discussing Second Quarter 2022 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Hits Moderna With Another Patent Infringement Suit-Related To COVID-19 Vaccine
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
Upgrades 
Via Benzinga
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
Pfizer Dives As CureVac Tees Up A Patent Suit Aimed At Its BioNTech-Partnered Covid Shot
The company isn't seeking an injunction, but wants "fair compensation." 
Via Investor's Business Daily
5 Best And Worst Performing Large-Cap Stocks In June 2022
Over the past decade or so, these large-cap stocks have outperformed their smaller peers. Let’s take a look at the five best and worst performing large-cap stocks in June 2022. 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
Where Alnylam Pharmaceuticals Stands With Analysts
Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 27, 2022
Upgrades 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Alnylam's Stock Gains Following FDA Nod For hATTR Amyloidosis Candidate
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ (NASDAQ: ALNY) lead drug candidate AMVUTTRA (Vutrisiran) for the treatment of the polyneuropathy of hereditary... 
Via Benzinga
Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Reports Positive Topline Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2022
Upgrades 
Via Benzinga
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Announces Publication of Preclinical Results Based on Novel Conjugate Technology That Facilitates Delivery of Short Interfering RNA to the Central Nervous System and Other Extrahepatic Tissues
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents New Results from the ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.